Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRACTECAL-PKPD Sub-study
NCT04081077Phase 3Unknown
- Sponsor
- Médecins Sans Frontières
- Start
- Aug 2019
- Primary completion
- Sep 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of bedaquiline, pretomanid and linezolid in multidrug-resistant tuberculosis (MDR-TB) and Extensively drug-resistant tuberculosis (XDR-TB) (3 arms), sponsored by Médecins Sans Frontières. Primary endpoints: Maximum Plasma Concentration at 72 weeks, Area Under the Curve at 72 weeks and 4 more. Status: unknown.
02
Drugs
bedaquilinepretomanidlinezolid
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)Extensively drug-resistant tuberculosis (XDR-TB)
Beyond the preview
Go deeper on NCT04081077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04081077.